NCT lookup

Pull any trial record directly from ClinicalTrials.gov.

Oxaliplatin and Docetaxel Followed by Cetuximab for Head and Neck Cancer

TerminatedPhase 2

Sponsor: University of Kansas Medical Center

Conditions: Head and Neck Cancer, Carcinoma, Squamous

Interventions: Oxaliplatin, Docetaxel, Cetuximab

Countries: United States

A study of Oxaliplatin and Docetaxel followed by Cetuximab for head and neck cancer patients to determine their effect on the control and reduction of tumor size

Eligibility overview

Sex: ALL

Age: 18 Years to —

Healthy volunteers: No

Study type: INTERVENTIONAL

Eligibility criteria

Inclusion Criteria:

* Histologically or cytologically confirmed recurrent SCCHN
* 18 years or older
* Tumor site accessible by biopsy
* Measurable disease
* Receiving no other therapy
* ECOG performance status 0-1
* Adequate bone marrow, renal function and hepatic function

Exclusion Criteria:

* Active infection or fever within 3 days of treatment
* Active CNS metastases
* Prior malignancy within 5 years
* Hypersensitivity to study drugs
* Chemotherapy within 30 days of treatment
* Concurrent investigational therapy within 30 days
* Radiotherapy of more than 25% of bone marrow
* Peripheral neuropathy of grade 2 or greater
* Pregnant or lactating patients
* History of allogeneic transplant
* Active or previously treated HIV or Hepatitis B or C
* Patients with a tracheostomy

Locations (1)

Kansas City, Kansas, United States